Microsoft-Based Generative AI Successfully Used for Clinical Trial Participant Screening—Mass General Brigham, Huge Promise but Risks

Mass General Brigham researchers find generative AI holds promise for increasing clinical trial screening efficiency, but as TrialSite has reported from other studies involving large language model-based generative AI, safeguards are needed. The team was granted complimentary access to Microsoft-based Azure OpenAI GPT-4V. However, the authors note that Microsoft had no access to the data used and was not involved in the analysis, interpretation of data, or writing of the study

The Opportunity